Building a Core Business within the Healthcare Business
First written in FY2017-Q1. 14 of 26 entries say "Advanced", first in FY2017-Q3. Latest entry: 2026-09-11.
1 other company's latest entry also says "Advanced".
- 2026-09-11AdvancedOther Disclosures
「We are promoting the development and launch of GeneSoC-specific in vitro diagnostic pharmaceuticals and research reagents for respiratory infections and other conditions, and will contribute to the diagnosis, prevention and treatment of infectious diseases through these products.」
The GeneSoC-specific in vitro diagnostic pharmaceutical business progressed to the launch of a new influenza virus nucleic acid kit. - FY2025-H1AdvancedAnnual report
「As part of its diagnostic-business initiatives, the company is focusing on expanding sales of in vitro diagnostics, including SARS coronavirus nucleic acid detection kits and influenza-virus nucleic acid kits, and is promoting the development of GeneSoC-specific research-use reagents and in vitro diagnostics, including the launch of a Bordetella pertussis detection kit in June 2024. In October 2024, it also launched the genetic analysis system GeneSoC mini 2, an improved version of the existing GeneSoC mini.」
In the healthcare and diagnostic businesses centred on infectious-disease-related activities, the product rollout advanced to the launch of the Bordetella pertussis detection kit and GeneSoC mini 2. - FY2023AdvancedAnnual report
「The company launched the in vitro diagnostic COVID-19 nucleic acid detection kit GeneSoC SARS-CoV-2 N2 Detection Kit in April 2022, the influenza-virus nucleic acid kit GeneSoC Influenza Virus A/B Detection Kit in November of the same year, and the research-use instrument GeneSoC miniR, an ultra-fast real-time PCR system developed for the life science and analytical science markets, in March 2023.」
In the healthcare and diagnostic businesses centred on infectious-disease-related activities, the product rollout advanced to the launch of products for COVID-19 and influenza, as well as the research-use instrument GeneSoC miniR. - FY2023-Q2AdvancedAnnual report
「The company also obtained manufacturing and marketing approval in August of the same year for the GeneSoC Influenza Virus A/B Detection Kit as an in vitro diagnostic, and launched it in November of the same year.」
In the healthcare business centred on infectious-disease-related activities, the product rollout advanced to obtaining approval and launching the GeneSoC influenza-virus detection kit as an in vitro diagnostic. - FY2023-Q1AdvancedAnnual report
「The company launched the COVID-19 nucleic acid detection kit GeneSoC SARS-CoV-2 N2 Detection Kit in April 2022.」
In the healthcare and diagnostic businesses centred on infectious-disease-related activities, the product rollout advanced to the launch of a GeneSoC-related COVID-19 nucleic acid detection kit. - FY2022-Q3AdvancedAnnual report
「As part of its diagnostic-business initiatives, the company launched a PCR pretreatment kit for detecting COVID-19 in July 2021 and the genetic analysis system GeneSoC mini in November of the same year.」
In the healthcare and diagnostic businesses centred on infectious-disease-related activities, the product rollout advanced with the launch of the PCR pretreatment kit and GeneSoC mini. - FY2022-Q2RestatedAnnual report
「In addition to working to promote the adoption of the microfluidic genetic quantification system GeneSoC and ensure a stable supply of reagents, the company launched a PCR pretreatment kit for detecting COVID-19 in July 2021」
Under the consolidation of the healthcare business around infectious-disease-related activities and its integration with the prescription pharmaceutical business, the company is working to promote and supply diagnostic instruments and reagents. - FY2021-Q3RestatedAnnual report
「Sales of Rubysta, an environmental disinfectant and cleaner, increased amid the spread of COVID-19.」
The company reports increased Rubysta sales under its policy of consolidating the healthcare business in areas related to infectious diseases. - FY2021-Q2RestatedAnnual report
「Beginning this fiscal year, under the new medium-term management plan “HOPE100-Stage 3- (FY2020-FY2023),” the group is consolidating its healthcare business in areas centred on infectious diseases and promoting its integration with the prescription pharmaceutical business.」
The company is reaffirming its direction of consolidating the healthcare business in areas related to infectious diseases and integrating it with the prescription pharmaceutical business. - FY2021-Q1ReframedAnnual report
「Beginning this fiscal year, under the new medium-term management plan “HOPE100-Stage 3- (FY2020-FY2023),” the group is consolidating its healthcare business in areas centred on infectious diseases and promoting its integration with the prescription pharmaceutical business.」
The effort to build a core healthcare business has again been defined as consolidating operations in areas centred on infectious diseases and integrating them with the prescription pharmaceutical business. - FY2020AdvancedAnnual report
「Amid increased demand associated with the spread of COVID-19, both products performed above the previous fiscal year. As a result, segment revenue was ¥6,383 million, up 10.8% from the previous fiscal year, and segment profit was ¥736 million, up 268.9%.」
Against a backdrop of increased demand for environmental hygiene products, healthcare-business revenue increased 10.8% from the previous fiscal year and segment profit increased 268.9%. - FY2020-Q3Slight revenue decline, substantial profit increaseAnnual report
「Rubysta, the main environmental disinfectant and cleaner, performed above the previous year, but sales of Milton, a disinfectant for baby bottles, nipples, utensils, and other items, declined. As a result, segment revenue was ¥4,390 million, down 0.6% year on year, while segment profit was ¥465 million, up 172.1%.」
Although Rubysta grew, revenue edged down due to lower sales of Milton, while segment profit increased 172.1% year on year. - FY2020-Q2AdvancedAnnual report
「The company promoted the medium-term management plan's development strategy of “Building a core business through growth in environmental hygiene and stronger collaboration with existing businesses.” Rubysta, the main environmental disinfectant and cleaner, performed above the previous year, resulting in segment revenue of ¥2,793 million, up 0.5% year on year, and segment profit of ¥225 million, up 739.7%.」
In the environmental hygiene business, Rubysta exceeded the previous year, while revenue increased 0.5% year on year and segment profit increased 739.7%. - FY2020-Q1Revenue decline and profit improvementAnnual report
「Rubysta, the main environmental disinfectant and cleaner, performed above the previous year, but due mainly to lower sales of Milton, a disinfectant for baby bottles, nipples, utensils, and other items, segment revenue was ¥1,341 million, down 3.9% year on year, while segment profit was ¥72 million, compared with a segment loss of ¥8 million in the previous year.」
Although Rubysta exceeded the previous year, lower sales of Milton and other products resulted in a 3.9% year-on-year decline in healthcare-business revenue. Segment profit improved from a loss in the previous year to ¥72 million. - FY2019WorsenedAnnual report
「Rubysta, the main environmental disinfectant and cleaner, performed above the previous year, but lower sales of other products resulted in segment revenue of ¥5,761 million, down 3.0% from the previous fiscal year. Segment profit was ¥199 million, up 6.6%.」
Rubysta grew and profit increased, but the decline in other products resulted in a 3.0% decrease in healthcare-business revenue from the previous fiscal year. - FY2019-Q3WorsenedAnnual report
「The main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, performed above the previous year. However, due to lower sales of other products, segment revenue was ¥4,415 million, down 0.5% year on year, and segment profit was ¥171 million, down 26.5%.」
Although the main products exceeded the previous year, the decline in other products resulted in lower healthcare-business revenue, while segment profit also fell 26.5% year on year. - FY2019-Q2WorsenedAnnual report
「The main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, performed above the previous year. However, due to lower sales of other products, segment revenue was ¥2,779 million, down 0.1% year on year, and segment profit was ¥26 million, down 64.3%.」
Although the main products exceeded the previous year, the decline in other products resulted in lower healthcare-business revenue, while segment profit also fell 64.3% year on year. - FY2019-Q1WorsenedAnnual report
「The company promoted the medium-term management plan's development strategy of “Building a core business through growth in environmental hygiene and stronger collaboration with existing businesses.” As the main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, performed above the previous year, segment revenue was ¥1,396 million, up 3.7% year on year, while the segment recorded a loss of ¥8 million, compared with segment profit of ¥15 million in the previous year.」
Although sales of environmental hygiene products rose 3.7% year on year, the healthcare business swung from segment profit in the previous year to a segment loss of ¥8 million. - FY2018AdvancedAnnual report
「Sales of the hand-hygiene product range launched in the previous fiscal year increased. The company will continue working to further expand its environmental hygiene business. During the fiscal year, it also entered the diagnostic business to identify the causative bacteria and viruses of infectious diseases. The company will promote growth toward its next core business.」
In addition to expanding the hand-hygiene product range, the company entered the diagnostic business to identify the causative bacteria and viruses of infectious diseases, moving on to explore its next core business. - FY2018-Q3AdvancedAnnual report
「To achieve the medium-term management plan's development strategy of “Building a core business through growth in environmental hygiene and stronger collaboration with existing businesses,” the company worked to expand its environmental hygiene product lineup and increase sales. In addition to growth in the main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, the hand-hygiene product range introduced through the sales and distribution partnership with Air Liquide Japan Ltd. beginning in March 2017 contributed to sales. Sales of environmental hygiene, over-the-counter medicines, and other products exceeded the previous year. As a result, segment revenue was ¥4,438 million, up 2.6% year on year, and segment profit was ¥232 million, up 583.2%.」
The continued expansion of the environmental hygiene product lineup and sales of the hand-hygiene product range contributed to revenue growth in the healthcare business, which recorded revenue of ¥4,438 million, up 2.6% year on year, and segment profit of ¥232 million, up 583.2%. - FY2018-Q2AdvancedAnnual report
「Sales of environmental hygiene, over-the-counter medicines, and other products exceeded the previous year, supported by growth in the main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, as well as sales of the hand-hygiene product range introduced through the sales and distribution partnership with Air Liquide Japan Ltd. beginning in March 2017. As a result, segment revenue was ¥2,781 million, up 3.3% year on year, and segment profit was ¥75 million, compared with a segment loss of ¥27 million in the previous year.」
The expansion of environmental hygiene products, particularly sales of the hand-hygiene product range, contributed to higher revenue in the healthcare business, and segment profit turned positive from a loss in the previous year. - FY2018-Q1AdvancedAnnual report
「Sales of environmental hygiene, over-the-counter medicines, and other products exceeded the previous year, supported by growth in the main products Rubysta, an environmental disinfectant and cleaner, and Milton, a disinfectant for baby bottles, nipples, utensils, and other items, as well as sales of the hand-hygiene product range introduced through the January 2017 sales and distribution partnership with Air Liquide Japan Ltd. As a result, segment revenue was ¥1,346 million, up 3.9% year on year, and segment profit was ¥15 million, compared with a segment loss of ¥35 million in the previous year.」
Sales of environmental hygiene products contributed to higher revenue in the healthcare business, and segment profit turned positive from a loss in the previous year. - FY2017AdvancedAnnual report
「As a measure to strengthen its environmental hygiene business, Kyorin Pharmaceutical Co., Ltd. entered into an agreement with Air Liquide Japan Ltd. in January 2017 concerning a sales and distribution partnership for a range of hand-hygiene products in the Japanese market, and began selling the products in March of that year. The company will continue working to expand its environmental hygiene product lineup with the aim of building a core business within its healthcare business.」
The initiative to make environmental hygiene a core part of the healthcare business took concrete shape with the start of sales of the hand-hygiene product range. - FY2017-Q3AdvancedAnnual report
「As a measure to strengthen its environmental hygiene business, Kyorin Pharmaceutical Co., Ltd. entered into an agreement with Air Liquide Japan Ltd. in January 2017 concerning a sales and distribution partnership for a range of hand-hygiene products in the Japanese market. The company is working to expand its environmental hygiene product lineup and promote growth, with the aim of building a core business within its healthcare business. Sales under the partnership were scheduled to begin around spring 2017.」
The company entered the stage of building a core healthcare business by forming a specific sales and distribution partnership in the environmental hygiene field and moving forward with product-line expansion and growth. - FY2017-Q2RestatedAnnual report
「In the healthcare business, we are promoting the development of a core business.」
The company continues to develop core businesses in its healthcare business. - FY2017-Q1First statedAnnual report
「In the healthcare business, we are promoting the development of a core business.」
The Group is building a core business in healthcare, which comprises skincare, environmental hygiene and OTC pharmaceuticals, among other areas.